| 2026 |
| 03/06 | 1,651 | 1,662 | 1,639 | 1,660 | -0.3% | 100,500 | 995億976万 | -0.48% |
| 03/05 | 1,675 | 1,683 | 1,661 | 1,665 | +1.46% | 95,000 | 998億949万 | -0.06% |
| 03/04 | 1,650 | 1,656 | 1,631 | 1,641 | -1.74% | 229,300 | 983億7079万 | -1.38% |
| 03/03 | 1,677 | 1,685 | 1,667 | 1,670 | -1.59% | 92,400 | 1001億922万 | +0.36% |
| 03/02 | 1,723 | 1,723 | 1,685 | 1,697 | -1.62% | 149,300 | 1017億2775万 | +2.11% |
| 02/27 | 1,704 | 1,725 | 1,702 | 1,725 | +0.88% | 96,200 | 1034億623万 | +3.92% |
| 02/26 | （IR情報）13:00 委任型執行役員制度導入及び執行役員人事に関するお知らせ |
| 02/26 | 1,698 | 1,716 | 1,694 | 1,710 | +0.71% | 81,500 | 1025億704万 | +3.39% |
| 02/25 | 1,707 | 1,709 | 1,694 | 1,698 | -0.7% | 98,200 | 1017億8769万 | +2.91% |
| 02/24 | 1,696 | 1,712 | 1,680 | 1,710 | +1.36% | 108,900 | 1025億704万 | +3.83% |
| 02/20 | 1,701 | 1,703 | 1,674 | 1,687 | -0.82% | 77,300 | 1011億2829万 | +2.68% |
| 02/19 | 1,695 | 1,712 | 1,690 | 1,701 | +0.59% | 140,600 | 1019億6753万 | +3.66% |
| 02/18 | 1,676 | 1,692 | 1,672 | 1,691 | +1.74% | 67,400 | 1013億6807万 | +3.24% |
| 02/17 | 1,671 | 1,678 | 1,661 | 1,662 | -0.3% | 80,600 | 996億2965万 | +1.65% |
| 02/16 | 1,669 | 1,670 | 1,655 | 1,667 | +0.06% | 71,100 | 999億2938万 | +2.14% |
| 02/13 | 1,672 | 1,676 | 1,651 | 1,666 | -0.24% | 71,400 | 998億6943万 | +2.21% |
| 02/12 | 1,676 | 1,682 | 1,670 | 1,670 | +0.3% | 105,500 | 1001億922万 | +2.71% |
| 02/10 | 1,660 | 1,676 | 1,660 | 1,665 | +0.24% | 112,900 | 998億949万 | +2.71% |
| 02/09 | 1,665 | 1,676 | 1,654 | 1,661 | +0.73% | 142,300 | 995億6970万 | +2.72% |
| 02/06 | 1,657 | 1,664 | 1,645 | 1,649 | -0.3% | 148,600 | 988億5036万 | +2.3% |
| 02/05 | 1,674 | 1,680 | 1,650 | 1,654 | +0.36% | 234,600 | 991億5009万 | +2.86% |
| 02/04 | （IR情報）14:00 インフルエンザウイルス核酸キット「GeneSoC FluA⁄B検出キット」の製造販売承認取得について |
| 02/04 | （IR情報）14:00 2026年3月期第3四半期決算短信〔日本基準〕(連結) |
| 02/04 | （IR情報）14:00 2026年3月期第3四半期決算補足資料 |
| 02/04 | 1,643 | 1,666 | 1,630 | 1,648 | +0.67% | 186,600 | 987億9041万 | +2.74% |
| 02/03 | 1,640 | 1,649 | 1,636 | 1,637 | +0.12% | 81,600 | 981億3101万 | +2.38% |
| 02/02 | 1,635 | 1,651 | 1,632 | 1,635 | +0.93% | 156,600 | 980億1112万 | +2.51% |
| 01/30 | 1,614 | 1,624 | 1,610 | 1,620 | +0.37% | 116,800 | 971億1193万 | +1.76% |
| 01/29 | 1,587 | 1,614 | 1,575 | 1,614 | +0.88% | 114,100 | 967億5226万 | +1.64% |
| 01/28 | 1,616 | 1,616 | 1,589 | 1,600 | -1.48% | 91,900 | 959億1302万 | +1.01% |
| 01/27 | 1,615 | 1,626 | 1,605 | 1,624 | -0.25% | 109,300 | 973億5172万 | +2.72% |
| 01/26 | 1,620 | 1,634 | 1,620 | 1,628 | -0.73% | 91,000 | 975億9150万 | +3.3% |
| 01/23 | 1,638 | 1,645 | 1,628 | 1,640 | +0.86% | 103,700 | 983億1085万 | +4.39% |
| 01/22 | 1,604 | 1,627 | 1,599 | 1,626 | +1.75% | 94,300 | 974億7161万 | +3.83% |
| 01/21 | 1,594 | 1,607 | 1,592 | 1,598 | -0.5% | 97,800 | 957億9313万 | +2.44% |
| 01/20 | 1,610 | 1,613 | 1,596 | 1,606 | -0.31% | 87,400 | 962億7269万 | +3.21% |
| 01/19 | 1,620 | 1,620 | 1,601 | 1,611 | -0.56% | 65,700 | 965億7242万 | +3.8% |
| 01/16 | 1,610 | 1,620 | 1,605 | 1,620 | -0.12% | 92,400 | 971億1193万 | +4.65% |
| 01/15 | 1,625 | 1,635 | 1,613 | 1,622 | -0.49% | 106,700 | 972億3182万 | +5.12% |
| 01/14 | 1,619 | 1,639 | 1,618 | 1,630 | +0.56% | 106,100 | 977億1139万 | +6.05% |
| 01/13 | 1,610 | 1,626 | 1,597 | 1,621 | +1.38% | 130,000 | 971億7188万 | +5.88% |
| 01/09 | 1,597 | 1,616 | 1,597 | 1,599 | +0.13% | 164,000 | 958億5307万 | +4.92% |
| 01/08 | 1,572 | 1,597 | 1,571 | 1,597 | +1.59% | 150,500 | 957億3318万 | +5.07% |
| 01/07 | 1,558 | 1,574 | 1,549 | 1,572 | +0.77% | 94,600 | 942億3454万 | +3.69% |
| 01/06 | 1,562 | 1,577 | 1,549 | 1,560 | +0.32% | 172,700 | 935億1519万 | +3.04% |
| 01/05 | （IR情報）15:30 ニューキノロン系経口抗菌剤「ラスビック錠」の中東9か国における独占的販売契約締結のお知らせ |
| 01/05 | 1,540 | 1,557 | 1,540 | 1,555 | +1.17% | 91,000 | 932億1547万 | +2.91% |
| 2025 |
| 12/30 | 1,555 | 1,555 | 1,537 | 1,537 | -1.16% | 76,900 | 921億3645万 | +1.92% |
| 12/29 | 1,537 | 1,556 | 1,537 | 1,555 | +1.04% | 134,400 | 932億1547万 | +3.25% |
| 12/26 | 1,540 | 1,542 | 1,532 | 1,539 | +0.13% | 54,600 | 922億5634万 | +2.4% |
| 12/25 | 1,545 | 1,545 | 1,532 | 1,537 | +0.26% | 60,100 | 921億3645万 | +2.6% |
| 12/24 | 1,550 | 1,554 | 1,527 | 1,533 | -0.9% | 77,800 | 918億9666万 | +2.61% |
| 12/23 | 1,524 | 1,548 | 1,524 | 1,547 | +1.71% | 141,900 | 927億3590万 | +3.9% |
| 12/22 | （5%ルール）Kopernik Global Investers, LLC（7.64%） |
| 12/22 | 1,525 | 1,532 | 1,518 | 1,521 | +0.2% | 151,700 | 911億7731万 | +2.49% |
| 12/19 | 1,527 | 1,527 | 1,514 | 1,518 | -0.65% | 462,100 | 909億9748万 | +2.57% |
| 12/18 | 1,506 | 1,534 | 1,499 | 1,528 | +1.66% | 180,400 | 915億9693万 | +3.59% |
| 12/17 | 1,500 | 1,507 | 1,492 | 1,503 | -0.13% | 94,400 | 900億9829万 | +2.24% |
| 12/16 | 1,506 | 1,514 | 1,497 | 1,505 | -0.2% | 124,000 | 902億1818万 | +2.73% |
| 12/15 | 1,499 | 1,509 | 1,492 | 1,508 | +1.55% | 126,800 | 903億9802万 | +3.29% |
| 12/12 | 1,506 | 1,514 | 1,476 | 1,485 | -0.87% | 168,900 | 890億1927万 | +1.99% |
| 12/11 | 1,510 | 1,512 | 1,494 | 1,498 | -0.53% | 126,600 | 897億9857万 | +3.1% |
| 12/10 | 1,488 | 1,507 | 1,488 | 1,506 | +0.94% | 118,500 | 902億7813万 | +3.93% |
| 12/09 | 1,493 | 1,494 | 1,479 | 1,492 | -0.33% | 137,600 | 894億3889万 | +3.25% |
| 12/08 | 1,494 | 1,502 | 1,487 | 1,497 | +0.81% | 206,800 | 897億3862万 | +3.81% |
| 12/05 | 1,467 | 1,495 | 1,467 | 1,485 | +1.09% | 108,000 | 890億1927万 | +3.27% |
| 12/04 | 1,471 | 1,472 | 1,461 | 1,469 | +0.2% | 75,300 | 880億6014万 | +2.44% |
| 12/03 | 1,476 | 1,484 | 1,466 | 1,466 | -1.35% | 114,400 | 878億8030万 | +2.45% |
| 12/02 | 1,504 | 1,504 | 1,477 | 1,486 | -1.26% | 125,500 | 890億7922万 | +3.84% |
| 12/01 | 1,515 | 1,519 | 1,497 | 1,505 | -0.66% | 152,700 | 902億1818万 | +5.32% |
| 11/28 | 1,485 | 1,515 | 1,485 | 1,515 | +2.02% | 180,200 | 908億1764万 | +6.24% |
| 11/27 | 1,485 | 1,489 | 1,477 | 1,485 | 0% | 70,300 | 890億1927万 | +4.36% |
| 11/26 | 1,484 | 1,488 | 1,477 | 1,485 | +0.61% | 94,700 | 890億1927万 | +4.43% |
| 11/25 | 1,484 | 1,490 | 1,470 | 1,476 | -0.34% | 160,800 | 884億7976万 | +3.94% |
| 11/21 | 1,433 | 1,481 | 1,432 | 1,481 | +3.57% | 347,700 | 887億7949万 | +4.44% |
| 11/20 | 1,425 | 1,435 | 1,425 | 1,430 | +0.85% | 122,500 | 857億2226万 | +0.99% |
| 11/19 | （IR情報）13:00 世界初のミトコンドリア病治療薬「MA-5」の第2相臨床試験を開始－難聴を有するミトコンドリア病患者を対象－ |
| 11/19 | 1,418 | 1,426 | 1,409 | 1,418 | 0% | 118,200 | 850億291万 | +0.14% |
| 11/18 | 1,430 | 1,434 | 1,410 | 1,418 | -0.7% | 141,900 | 850億291万 | +0.07% |
| 11/17 | 1,411 | 1,432 | 1,411 | 1,428 | +1.2% | 131,400 | 856億237万 | +0.71% |
| 11/14 | 1,406 | 1,417 | 1,403 | 1,411 | +0.36% | 101,300 | 845億8329万 | -0.56% |
| 11/13 | 1,403 | 1,413 | 1,402 | 1,406 | +0.79% | 130,200 | 842億8357万 | -1.06% |
| 11/12 | 1,405 | 1,416 | 1,392 | 1,395 | +0.65% | 224,400 | 836億2416万 | -2.04% |
| 11/11 | 1,381 | 1,389 | 1,359 | 1,386 | +0.51% | 323,100 | 830億8465万 | -2.81% |
| 11/10 | 1,380 | 1,382 | 1,365 | 1,379 | -1.92% | 239,300 | 826億6503万 | -3.5% |
| 11/10 | （IR情報）9:00 2026年3月期第2四半期(中間期)決算説明会資料 |
| 11/07 | （IR情報）15:30 2026年3月期第2四半期(中間期)決算補足資料 |
| 11/07 | （IR情報）15:30 2026年3月期第2四半期(中間期)決算短信〔日本基準〕(連結) |
| 11/07 | 1,395 | 1,409 | 1,395 | 1,406 | +0.93% | 89,400 | 842億8357万 | -1.82% |
| 11/06 | 1,395 | 1,406 | 1,393 | 1,393 | -0.57% | 67,100 | 835億427万 | -2.86% |
| 11/05 | 1,418 | 1,429 | 1,395 | 1,401 | -1.06% | 126,700 | 839億8384万 | -2.51% |
| 11/04 | 1,405 | 1,421 | 1,404 | 1,416 | +0.78% | 117,000 | 848億8302万 | -1.73% |
| 10/31 | 1,394 | 1,408 | 1,394 | 1,405 | +0.86% | 118,200 | 842億2362万 | -2.84% |
| 10/30 | 1,388 | 1,399 | 1,384 | 1,393 | +0.43% | 110,100 | 835億427万 | -3.93% |
| 10/29 | 1,415 | 1,415 | 1,387 | 1,387 | -1.91% | 163,000 | 831億4460万 | -4.67% |
| 10/28 | 1,443 | 1,443 | 1,414 | 1,414 | -2.28% | 102,200 | 847億6313万 | -3.15% |
| 10/27 | 1,435 | 1,447 | 1,433 | 1,447 | +0.7% | 59,300 | 867億4134万 | -1.16% |
| 10/24 | 1,450 | 1,451 | 1,433 | 1,437 | -0.9% | 90,200 | 861億4188万 | -2.11% |
| 10/23 | 1,441 | 1,454 | 1,441 | 1,450 | +1.05% | 123,500 | 869億2117万 | -1.43% |
| 10/22 | 1,442 | 1,446 | 1,435 | 1,435 | -0.49% | 181,200 | 860億2199万 | -2.78% |
| 10/21 | 1,444 | 1,448 | 1,440 | 1,442 | +0.07% | 59,900 | 864億4161万 | -2.63% |
| 10/20 | 1,442 | 1,447 | 1,438 | 1,441 | +0.77% | 57,700 | 863億8166万 | -3.03% |
| 10/17 | 1,436 | 1,439 | 1,424 | 1,430 | -0.69% | 107,000 | 857億2226万 | -4.09% |
| 10/16 | 1,431 | 1,444 | 1,430 | 1,440 | +0.7% | 66,200 | 863億2172万 | -3.81% |
| 10/15 | 1,426 | 1,438 | 1,426 | 1,430 | +0.42% | 131,400 | 857億2226万 | -4.79% |
| 10/14 | 1,430 | 1,433 | 1,412 | 1,424 | -1.39% | 133,000 | 853億6259万 | -5.51% |
| 10/10 | 1,452 | 1,452 | 1,441 | 1,444 | -1.16% | 121,800 | 865億6150万 | -4.5% |
| 10/09 | 1,460 | 1,461 | 1,451 | 1,461 | -0.07% | 88,600 | 875億8058万 | -3.63% |
| 10/08 | 1,478 | 1,485 | 1,458 | 1,462 | -0.54% | 103,000 | 876億4052万 | -3.75% |
| 10/07 | 1,470 | 1,484 | 1,465 | 1,470 | +0.07% | 89,100 | 881億2009万 | -3.42% |
| 10/01 | （IR情報）8:30 SLE等の新規治療薬候補の日本における共同開発及びライセンス契約締結について |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
